Bivalirudin (CAS 128270-60-0) – Research Grade is a high-purity chemical compound.

Bivalirudin is a synthetic peptide of 20 amino acids, comprising D-Phe, Pro, Arg, Pro, Gly, Gly, Gly, Gly, Asn, Gly, Asp, Phe, Glu, Glu, Ile, Pro, Glu, Glu, Tyr, and Leu in sequence. A congener of hirudin (a naturally occurring drug found in the saliva of the medicinal leech), it a specific and reversible inhibitor of thrombin, and is used as an anticoagulant. It has a role as an anticoagulant and an EC 3.4.21.5 (thrombin) inhibitor.

Research Context

Research Applications

Bivalirudin is primarily studied for its applications in anticoagulation therapy, particularly in patients undergoing percutaneous coronary interventions (PCI). This peptide has been extensively researched in the context of cardiovascular diseases, where it serves as an alternative to traditional anticoagulants such as heparin. Bivalirudin has demonstrated efficacy in reducing thrombotic events while minimizing bleeding complications, making it a valuable tool in acute coronary syndrome management.

FDA-approved for use in patients undergoing PCI, Bivalirudin is marketed under the trade name Angiomax. Its therapeutic applications extend beyond coronary interventions, with ongoing research exploring its potential benefits in other areas, including stroke prevention and management of patients with heparin-induced thrombocytopenia (HIT).

History & Development

Bivalirudin was originally developed by the biotechnology company Biogen in the early 1990s. The compound underwent extensive clinical trials, leading to its FDA approval in 2000 for use in patients undergoing PCI. The trade name Angiomax reflects its application in angioplasty procedures. One of the notable design features of Bivalirudin is its synthetic origin, which allows for a high degree of enzyme resistance and a predictable pharmacokinetic profile, enhancing its utility in acute care settings.

Mechanism of Action

Bivalirudin functions as a direct thrombin inhibitor, binding to both the active site and exosite of thrombin. This dual binding mechanism effectively inhibits thrombin's ability to convert fibrinogen to fibrin, thereby preventing clot formation. By inhibiting thrombin, Bivalirudin also reduces platelet activation and aggregation, leading to a decrease in thrombus development. The compound's rapid onset and short half-life make it particularly suitable for use in acute settings, where immediate anticoagulation is necessary.

Clinical Data

Clinical studies have provided robust evidence for the efficacy of Bivalirudin in PCI procedures. For instance, the study conducted by Stone et al. published in the New England Journal of Medicine demonstrated that Bivalirudin use resulted in a significant reduction in major bleeding complications compared to heparin. The study, which was a Phase 3 trial, highlighted the compound's safety profile and effectiveness in a high-risk patient population. Additionally, published studies suggest that Bivalirudin may reduce the incidence of acute coronary events, making it a critical agent in the management of coronary artery disease.

How It Compares

When comparing Bivalirudin to other anticoagulants, several key differences emerge. For instance, compared to unfractionated heparin, Bivalirudin offers a more predictable pharmacokinetic profile and is associated with lower rates of bleeding complications. Additionally, unlike low molecular weight heparins such as Enoxaparin, Bivalirudin does not require monitoring of activated partial thromboplastin time (aPTT), simplifying its administration in acute care settings.

In the context of direct thrombin inhibitors, Bivalirudin is often evaluated alongside Argatroban and Dabigatran. While Argatroban is primarily used in patients with HIT, Bivalirudin's rapid onset and short duration of action make it more suitable for transient anticoagulation during procedures. Dabigatran, on the other hand, is utilized for long-term anticoagulation in atrial fibrillation, showcasing a different clinical application. Overall, Bivalirudin's unique mechanism and rapid action distinguish it from these related compounds.

Solubility & Storage

Bivalirudin is typically reconstituted using sterile water for injection or bacteriostatic water. The lyophilized form should be stored at controlled room temperature, while the reconstituted solution is generally recommended to be refrigerated at 2-8°C. Once reconstituted, Bivalirudin is typically stable for up to 24 hours when stored appropriately, necessitating careful handling to ensure efficacy.

Future Research Directions

Future research on Bivalirudin is exploring its applications in a variety of clinical scenarios beyond PCI. Researchers are investigating its potential role in the management of acute ischemic stroke and in patients with HIT, where traditional anticoagulants may pose risks. Additionally, there is emerging interest in studying Bivalirudin's effects in combination with other therapeutic agents to enhance its efficacy and safety profile. As ongoing studies continue to elucidate its full potential, Bivalirudin remains a significant focus in anticoagulation research.